Effect of pentavalent antimonial treatment on the histopathological and ultrastructural aspects of diffuse cutaneous leishmaniasis due to Leishmania amazonensis

European Journal of Dermatology

Volumn 6, Issue 4, 1996, Pages 264-267

  Bittencourt, Achiléa L ^b   Badaró, Roberta ^b   Costa, Jackson ^b   Barral, Aldina ^b   Badaró, Fernando ^b   Carvalho, Edgar M ^b  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^b NONE

Author keywords

Diffuse cutaneous leishmaniasis; IFN therapy; Leishmania amazonensis; Pathology of tegumentary leishmaniasis

Indexed keywords

GAMMA INTERFERON; MEGLUMINE ANTIMONATE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; HUMAN; LEISHMANIASIS;

EID: 0029992190     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Convit J, Pinard ME. Cutaneous leishmaniasis. The clinical and immunopathological spectrum in South America. In: Typanosomiasis and leishmaniasis with special reference to Chagas' disease. Ciba Foundation Symposium Elsevier, New York, 1974; 1: 159-69.
2. Bittencourt AL, Barral-Netto M. Leishmaniases. In: Doerr W, Seifert G, eds. Tropical pathology. Berlin: Springer-Verlag, 1995; 597-651.
3. Bittencourt AL, Barral A, Jesus AM, Almeida RP, Grimaldi JrG. In situ identification of L. amazonensis associated with diffuse cutaneous leishmaniasis in Bahia, Brazil. Mem Inst Oswaldo Cruz 1989; 84: 585-6.
4. Velasco O, Savarino SJ, Walton BC, Gam AA, Neva FA. Diffiuse cutaneous leishmaniasis in Mexico. Am J Trop Med Hyg 1989; 41: 280-8.
5. Barral A, Costa JML, Bittencourt AL, Barral-Netto M, Carvalho EM. Polar and sub-polar diffuse cutaneous leishmaniasis in Brazil. Clinical and immunopathological aspects. Int J Dermatol 1995; 34: 474-9.
6. Castes M, Agnelli A, Verde O, Rondon AJ. Characterization of the cellular immune response in American cutaneous leishmaniasis. Clin Immunol Immunopathol 1983; 27: 176-86.
7. Morierty P, Bittencourt AL, Pereira C, Teixeira R, Barreto C, Guimarães NA. Borderline cutaneous leishmaniasis. Clinical, immunological and histologicol differences from mucocutaneous leishmaniasis. Rev Inst Med Trop São Paulo 1978; 20: 15-21.
8. Murray HW, Cartelli DM. Killing of intracellular L. donovani by human monocluclear phagocytes. Evidence for oxygen-dependent and independent leishmanicidal activity. J Clin Invest 1983; 72: 1506-10.
9. Badaró R, Falcoff E, Badaró FS, Carvalho EM, Pedral-Sampaio D, Barral A, Carvalho JS, Barral-Netto M, Brandley M, Silva L, Bina JC, Teixeira R, Falcoff R, Rocha H, Ho JL, Johnson WD. Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma. New Engl J Med 1990; 322: 16-21.
10. Bittencourt AL, Freitas LAR, Pompeu ML, Vieira ML, Barral A. Distinct ultrastructural aspects in different biopsies of a single patient with diffuse cutaneous leishmaniasis. Mem Inst Oswaldo Cruz 1990; 85: 53-9.
11. Ridley DS, Ridley MJ. The evolution of the lesion in cutaneous leishmaniasis. J Pathol 1983; 141: 83-96.
12. Bittencourt AL, Barral A, Costa JML, Saldanha AC, Badaró F, Barral-Netto M, Freitas LAR. Diffuse cutaneous leishmaniasis with atypical aspects. Int J Dermatol 1992; 31: 568-70.
13. Pompeu ML, Freitas LA, Santos MLV, Barral A, Barral-Netto M. Leishmania amazonensis infection: a comparison of in vivo leishmanicidal mechanisms between immunized and naive infected BALB/c mice. Exp Parasitol 1992; 74: 169-76.
14. Bittencourt AL, Freitas LAR. Leishmaniose tegumentar difusa. Med Cutan Ibero Lot Amer 1983; 11: 265-70.
15. Itoh K, Shüba KI, Shimizu Y, Suzuki R, Kumagai K. Generation of activated killer (AK) cells by recombinant interleukin-2 (rIL-2) in collaboration with interferon gamma (IFNγ). J Immunol 1985; 134: 3124-9.